Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 3
Go back to Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 3| GALMED PHARMACEUTIC (NASDAQ: GLMD) | Delayed: 0.56 -0.02 (3.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.58 | 52 Week High | $9.70 | |||
| Open | $0.55 | 52 Week Low | $2.78 | |||
| Day High | $0.61 | P/E | N/A | |||
| Day Low | $0.53 | EPS | $0.00 | |||
| Volume | 755,194 | |||||
